The Impact of Genomic Prof ling for Novel Cancer Therapy–Recent Progress in Non-Small Cell Lung Cancer

作     者：Jingwu Xie Xiaoli Zhang 

作者机构：Department of Pediatrics Indiana University School of Medicine Indianapolis IN 46202 USA Department of Biochemistry and Molecular Biology Indiana University School of Medicine Indianapolis IN 46202 USA Department of Pharmacology and Toxicology Indiana University School of Medicine Indianapolis IN 46202 USA The Simon Cancer Center and The Wells Center for Pediatrics Research Indiana University School of Medicine Indianapolis IN 46202 USA 

出 版 物：《Journal of Genetics and Genomics》 (遗传学报（英文版）)

年 卷 期：2016年第43卷第1期

页      面：3-10页

核心收录：

学科分类：0710[理学-生物学] 1002[医学-临床医学] 1001[医学-基础医学(可授医学、理学学位)] 100214[医学-肿瘤学] 10[医学] 

基　　金：supported by the National Cancer Institute(Nos.R01CA155086 and R01CA94160) 

主　　题：Targeted therapy Lung cancer Gene mutation 

摘      要：There is high expectation for significant improvements in cancer patient care after completion of the human genome project in 2003. Through pains-taking analyses of genomic profiles in cancer patients, a number of targetable gene alterations have been discovered, with some leading to novel therapies, such as activating mutations of EGFR, BRAF and ALK gene fusions. As a result, clinical management of cancer through targeted therapy has finally become a reality for a subset of cancers, such as lung adenocarcinomas and melanomas. In this review, we summarize how gene mutation discovery leads to new treatment strategies using non-small cell lung cancer （NSCLC） as an example. We also discuss possible future implications of cancer genome analyses.